Tower Research Capital LLC TRC Trims Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Tower Research Capital LLC TRC lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 1.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,050 shares of the medical device company’s stock after selling 349 shares during the period. Tower Research Capital LLC TRC’s holdings in DexCom were worth $2,804,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc purchased a new stake in DexCom in the fourth quarter worth $25,000. Private Trust Co. NA increased its position in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after buying an additional 167 shares during the last quarter. Larson Financial Group LLC increased its position in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in shares of DexCom in the fourth quarter worth $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the transaction, the executive vice president now directly owns 105,602 shares in the company, valued at approximately $7,432,268.76. This represents a 10.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last three months. 0.32% of the stock is currently owned by company insiders.

DexCom Trading Down 3.6 %

NASDAQ DXCM opened at $66.11 on Tuesday. The firm has a market cap of $25.92 billion, a price-to-earnings ratio of 46.23, a PEG ratio of 2.30 and a beta of 1.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a one year low of $57.52 and a one year high of $139.24. The firm has a 50 day simple moving average of $74.62 and a 200-day simple moving average of $76.74.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have issued reports on DXCM shares. Citigroup upped their target price on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a report on Saturday, March 8th. Mizuho initiated coverage on shares of DexCom in a research report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 price target on the stock. Finally, Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $99.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.